Wave Life Sciences Q3 net loss $61.8M; first RNA editing in humans for AATD achieved

Wave Life Sciences Ltd.

2024-Q3 EPS reported -$0.97

Net loss $61.8M vs net income $7.3M in Q3 2023; revenue ($7.7M) vs $49.2M (including one-time events).
Cash $310.9M at Sep 30, 2024; plus ~$28M net proceeds from greenshoe; runway into 2027.
First-ever RNA editing in humans: WVE-006 in RestorAATion-2 showed mean M-AAT 6.9 µM at day 15 (60%+ of total AAT).
WVE-007 (INHBE GalNAc-siRNA) obesity clinical trial on track for 1Q 2025; preclinical data supports monotherapy and GLP-1 synergy.
WVE-003 HD: FDA open to caudate atrophy endpoint for accelerated approval; IND submission expected 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.